Heike Schlichthaar

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist

Victoria E R Parker, Darren Robertson, Tao Wang et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 117 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal, Wanzhu Tu, Alfredo E. Farjat et al. · Annals of Internal Medicine · 2023 · 88 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

Victoria Parker, Thuong Hoang, Heike Schlichthaar et al. · Diabetes Obesity and Metabolism · 2022 · 71 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Ellen Burgess, Rajiv Agarwal, Stefan D. Anker et al. · Diabetes Care · 2022 · 35 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17